Previous 10 | Next 10 |
-- Transformational Leader Brings Three Decades of Global Experience in Pharmaceutical and Biotechnology Product Development and Commercialization -- -- Paul J. Hastings Named Chair of the Board -- -- Dave Stack to Remain in Advisory Role through August 2025 -- TAMPA,...
BDC-1001 is a Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) in Phase 2 development for HER2-positive breast, colorectal, endometrial, and gastroesophageal cancers Poster detailing trial design and rationale to be presented at the 2023 San Antonio Breast Cancer Symposium on Wed...
2023-11-09 17:38:54 ET Bolt Biotherapeutics press release ( NASDAQ: BOLT ): Q3 GAAP EPS of -$0.43 beats by $0.03 . Revenue of $2.5M (+19.0% Y/Y) beats by $0.74M . Cash, cash equivalents, and marketable securities were $141.4 million as of September 30, 2023. ...
BDC-1001 program advances in multiple Phase 2 clinical studies in patients with HER2-positive colorectal, gastric, endometrial, and metastatic breast cancer, with recent updated data at ESMO showing improved clinical efficacy and longer durability; FDA Orphan Drug Designation granted for the BDC-...
Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
Bolt Biotherapeutics Inc. (BOLT) is expected to report $-0.49 for Q3 2023
REDWOOD CITY, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will participate in a fireside chat at the Stifel 2023 Healthcare C...
Updated safety data supports the selection of 20 mg/kg q2w as the recommended Phase 2 dose (RP2D) Improved efficacy with one partial response (PR) improving to a complete response (CR), two additional patients with long-term stable disease (SD), and three patients who have now received ther...
Company to debut preclinical data illustrating how the combination of trastuzumab ISAC and pertuzumab augments anti-tumor efficacy in multiple HER2+ tumor models relative to trastuzumab plus pertuzumab Company announces Claudin 18.2 ISAC program with a poster detailing in vitro and in vivo ex...
BDC-3042, a novel Dectin-2 agonistic antibody that stimulates the innate immune system, is being evaluated in a Phase 1/2 dose-escalation and expansion study in patients with a broad range of solid tumors REDWOOD CITY, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: ...
News, Short Squeeze, Breakout and More Instantly...
Bolt Biotherapeutics Inc. Company Name:
BOLT Stock Symbol:
NASDAQ Market:
Bolt Biotherapeutics Inc. Website:
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 147.2% to $0.705 on volume of 1,314,512,517 shares SiNtx Technologies Inc. (SINT) rose 132.0% to $0.1276 on volume of 976,185,336 shares Greenwave Technology Solutions Inc. (GWAV) r...
A look at the top 10 most actives in the United States SiNtx Technologies Inc. (SINT) rose 208.7% to $0.1698 on volume of 325,435,783 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 76.7% to $0.5039 on volume of 314,353,673 shares Greenwave Technology Solutions Inc. (GWAV) ros...
Refocusing pipeline to Phase 1 Dectin-2 agonist antibody BDC-3042 and next-generation Boltbody™ ISAC platform including new clinical candidate BDC- 4182 targeting Claudin 18.2 Bolt to cease further development of trastuzumab imbotolimod (BDC-1001) and reduce workforce by approx...